Shares of Moderna (NASDAQ: MRNA) were bouncing back by 3.6% as of 11:04 a.m. EDT on Tuesday after falling 6% on Monday. The rebound appears to be due to investors buying on the dip after digesting news that some top scientists are opposing booster doses for messenger RNA vaccines.
There's a pretty good case to be made that yesterday's sell-off of vaccine stocks was overdone. For one thing, it remains to be seen what impact that opposition to boosters will have on upcoming U.S. government decisions.
Image source: Getty Images.
More importantly, though, the U.S. has already bought enough COVID-19 vaccine doses to provide boosters for all Americans. Even if boosters aren't given a green light, it won't have much financial impact (if any) on Moderna over the near term.
In addition, the group of scientists that contributed to a paper published in The Lancet on Monday acknowledged that boosters might be required if the efficacy of current vaccines declines. Moderna could still benefit if boosters are indeed needed over the longer term.
The Food and Drug Administration is convening an advisory panel on Friday to discuss booster doses. Moderna's share price could experience another swing, either up or down, based on what the panel recommends.
10 stocks we like better than Moderna Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 9, 2021
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.